According to TipRanks, Turkaly is a 4-star analyst with an average return of 6.1% and a 52.51% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical, Haemonetics, and AxoGen.
Electrocore has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
ECOR market cap is currently $46.94M and has a P/E ratio of -2.34.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR:
- OPKO Health Announces Leadership Changes for BioReference Laboratories
- Minim Announces Executive Leadership Transition
- JMP Securities Reaffirms Their Hold Rating on NuVasive (NUVA)
- Stifel Nicolaus Sticks to Their Buy Rating for Sea (SE)
- Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08